Shares of Reata Pharmaceuticals RETA decreased in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 7.32% over the past year to ($1.32), which beat the estimate of ($2.08).
Revenue of $2,221,000 decreased by 27.73% from the same period last year, which beat the estimate of $1,250,000.
Guidance
Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.
Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 09, 2021
Time: 04:30 PM
Price Action
Company's 52-week high was at $186.82
52-week low: $76.34
Price action over last quarter: Up 14.04%
Company Description
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.